Clinical efficacy of radiotherapy combined with hyperbaric oxygen on the patients with pancreatic cancer and the impact on serum tumor markers

Abstract

Objective \nTo explore the clinical efficacy of radiotherapy combined with hyperbaric oxygen (HBO) on the patients with pancreatic cancer and the impact on serum tumor markers. \n \n \nMethods \nEighty-four patients with pancreatic cancer admitted into the hospital from January 2015 to September 2017 were selected as research objects, and were randomly and equally divided into the control group (n=42) and the observation group (n=42). The patients in the control group were given targeted radiotherapy, while the patients in the observation group were supplemented with HBO on the basis of the treatment as received by the control group. Then, plasma tumor marker carbohydrate antigen 199 (CA19-9), hypoxia inducing factor (HIF-1α) and vascular endothelial growth factor (VEGF), as well as clinical efficacy and adverse reactions were compared between the 2 groups before and after treatment. \n \n \nResults \nAfter treatment, the contents of CA19-9, HIF-1α and VEGF in the 2 groups were significantly reduced compared with those before treatment, and those of the observation group were significantly better than those in the control group. Total effective rate of the observation group was 64.28%, which was higher than that of the control group(40.48%). Statistical significance could be noted, when comparisons were made between the 2 groups (P 0.05). \n \n \nConclusion \nRadiotherapy combined with HBO therapy could increase radiotherapy response of tumor cells to radiotherapy through down-regulation of the levels of CA19-9, HIF-1α and VEGF, promote clinical efficacy, and further reduce adverse reactions. \n \n \nKey words: \nRadiotherapy;\xa0Hyperbaric oxygen;\xa0Pancreatic cancer;\xa0Serum tumor marker;\xa0Clinical efficacy